# Dermatomyositis: Skin Findings and Malignancy Screening

## Overview

Dermatomyositis (DM) is an inflammatory myopathy with characteristic cutaneous findings, classified among the idiopathic inflammatory myopathies alongside polymyositis and inclusion body myositis. It can present as classic dermatomyositis with both skin and muscle involvement, or as clinically amyopathic dermatomyositis (also called "dermatomyositis sine myositis"), in which skin findings occur without clinically significant muscle disease. Adult-onset DM carries a significant risk of associated internal malignancy, whereas juvenile DM represents a different disease spectrum in which calcinosis is more common and malignancy risk is absent.

## Pathognomonic and Characteristic Skin Findings

### Gottron Papules (Pathognomonic)

Gottron papules are violaceous-to-erythematous, flat-topped papules that overlie the metacarpophalangeal and interphalangeal joints and may also involve the elbows and knees. The key distinction from lupus is that DM involves the skin over the knuckles (dorsal surface), while lupus involves the skin between the knuckles in the interarticular spaces, sparing the joints. Over time, these papules evolve from erythematous to atrophic, hypopigmented lesions with telangiectasia.

### Heliotrope Rash (Pathognomonic)

The heliotrope rash consists of violaceous (lilac-colored) erythema and edema of the upper eyelids. It is typically bilateral and symmetric and can be quite subtle, presenting as a slight violaceous tinge accompanied by periorbital edema. The name derives from the heliotrope flower, which shares the same purple hue.

### V-Sign

The V-sign is an erythematous, photodistributed rash on the anterior chest and neck in a V-shaped pattern, corresponding to the area of habitual sun exposure.

### Shawl Sign

The shawl sign describes erythema distributed over the posterior shoulders, upper back, and posterior neck. It is photodistributed and named for its resemblance to a draped shawl.

### Holster Sign

The holster sign refers to violaceous erythema over the lateral thighs. It is relatively specific for DM and often overlooked during clinical examination.

### Mechanic's Hands

Mechanic's hands present as roughened, cracked, and fissured skin on the lateral and palmar aspects of the fingers, resembling the hands of a manual laborer. This finding is associated with anti-synthetase syndrome, particularly anti-Jo-1 and other anti-synthetase antibodies, and may also occur in antisynthetase syndrome without dermatomyositis.

### Periungual Changes

Periungual findings include nailfold telangiectasia with dilated, tortuous capillary loops visible on nailfold capillaroscopy, cuticular overgrowth with ragged cuticles, and periungual erythema.

### Other Cutaneous Features

**Poikiloderma** consists of a combination of atrophy, telangiectasia, and dyspigmentation (both hyper- and hypopigmentation) in sun-exposed areas. **Calcinosis cutis** refers to subcutaneous calcium deposits that are more common in juvenile DM and can ulcerate, extruding chalky material. **Flagellate erythema** manifests as linear streaks of erythema on the trunk, a finding also seen with bleomycin use. Scalp involvement produces erythema, scaling, and pruritus that may mimic seborrheic dermatitis or psoriasis, and can cause diffuse non-scarring alopecia. Panniculitis, or subcutaneous inflammation, is a rare association.

<image>Clinical photographs of the hallmark skin findings of dermatomyositis: Gottron papules over the knuckles, heliotrope rash of the eyelids, V-sign on the anterior chest, and shawl sign over the posterior shoulders</image>

## Myositis-Specific Antibodies (MSAs)

### Anti-Mi-2

Anti-Mi-2 antibodies are associated with classic DM featuring full skin findings and muscle disease. These patients generally have a good prognosis with responsive disease and carry a low malignancy risk.

### Anti-TIF1-gamma (p155/140)

Anti-TIF1-gamma antibodies carry the strongest association with malignancy in adult-onset DM, with approximately 60-80% of anti-TIF1-gamma-positive adult DM patients having an associated cancer. The most commonly associated malignancies include ovarian, breast, lung, gastrointestinal, and lymphoma. The presence of this antibody warrants extensive malignancy screening.

### Anti-MDA5 (CADM-140)

Anti-MDA5 antibodies are associated with clinically amyopathic DM, where skin findings occur without significant myopathy. The most feared complication is **rapidly progressive interstitial lung disease (RP-ILD)**, which carries a mortality rate of approximately 50% within 6 months without aggressive treatment. Characteristic mucocutaneous findings include skin ulceration (especially over Gottron papules and elbows), oral ulcers, palmar papules, and painful digital ulcers. This antibody profile is more common in East Asian populations.

### Anti-NXP2 (MJ)

Anti-NXP2 antibodies are associated with calcinosis, particularly in juvenile DM. In adults, they carry a moderate malignancy risk and are linked to severe muscle disease and dysphagia.

### Anti-SAE

Anti-SAE antibodies are associated with an initial amyopathic DM presentation that later develops myositis. There is moderate malignancy risk, and dysphagia is common.

### Anti-Jo-1 (and Other Anti-Synthetase Antibodies)

Anti-Jo-1 is the most common anti-synthetase antibody and defines the **anti-synthetase syndrome**, which includes myositis, interstitial lung disease, arthritis, mechanic's hands, Raynaud phenomenon, and fever. Other anti-synthetase antibodies include anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, and anti-KS. ILD is the leading cause of morbidity and mortality in this syndrome.

| MSA | Clinical Phenotype | Malignancy Risk | Key Complications |
|-----|-------------------|----------------|-------------------|
| Anti-Mi-2 | Classic DM (skin + muscle) | Low | Good prognosis, treatment-responsive |
| Anti-TIF1-gamma | Adult DM | High (60–80%) | Ovarian, breast, lung, GI cancers |
| Anti-MDA5 | Clinically amyopathic DM | Low | Rapidly progressive ILD (~50% mortality) |
| Anti-NXP2 | Calcinosis; severe myopathy | Moderate (adults) | Dysphagia; calcinosis (juvenile DM) |
| Anti-SAE | Amyopathic initially, then myositis | Moderate | Dysphagia |
| Anti-Jo-1 | Antisynthetase syndrome | Low | ILD, arthritis, mechanic's hands, Raynaud |

<image>Table summarizing the myositis-specific antibodies with their associated clinical phenotypes, malignancy risk, and key complications including anti-TIF1-gamma (malignancy), anti-MDA5 (rapidly progressive ILD), and anti-Jo-1 (antisynthetase syndrome)</image>

## Histopathology

The histopathology of dermatomyositis shows **interface dermatitis** in a vacuolar pattern, similar to lupus. There is a sparse perivascular lymphocytic infiltrate, prominent dermal mucin deposition (Alcian blue-positive), and epidermal atrophy. Basement membrane zone thickening may be present but is typically less prominent than in lupus. DM cannot be reliably distinguished from lupus on histology alone, making clinical correlation essential. The distribution of the rash, muscle symptoms, and serologies are what distinguish DM from lupus.

## Diagnosis

### Bohan and Peter Criteria (Classic)

The classic diagnostic criteria include symmetric proximal muscle weakness, elevated muscle enzymes (CK, aldolase, LDH, AST, ALT), electromyographic changes showing a myopathic pattern, muscle biopsy findings of perifascicular atrophy (characteristic of DM) with perivascular inflammation, and a characteristic skin rash.

### Clinically Amyopathic DM (CADM)

Clinically amyopathic DM is defined by characteristic skin findings present for six months or more without clinical muscle weakness, with normal or minimally elevated muscle enzymes. This form represents approximately 20% of DM cases and is important to recognize because of the ILD risk, particularly in patients who are anti-MDA5 positive.

### Workup

The diagnostic workup should include muscle enzymes (CK, aldolase, LDH, AST, ALT), a myositis-specific antibody panel (anti-Mi-2, anti-TIF1-gamma, anti-MDA5, anti-NXP2, anti-SAE, anti-Jo-1), and EMG if the diagnosis is uncertain. MRI of proximal muscles showing edema patterns on STIR sequences is increasingly replacing muscle biopsy at many centers, though muscle biopsy remains valuable for demonstrating perifascicular atrophy and complement-mediated microangiopathy. Skin biopsy reveals interface dermatitis with mucin. Pulmonary function tests and HRCT of the chest should screen for ILD, especially in patients positive for anti-MDA5 or anti-Jo-1. Malignancy screening, nailfold capillaroscopy to evaluate for dilated tortuous capillary loops, and age-appropriate evaluations round out the assessment.

## Malignancy Screening (The Controversy)

### Association

Adult-onset DM carries a 3-8 times increased risk of malignancy compared to the general population, with the risk highest in the first 1-3 years after DM diagnosis. The most commonly associated cancers are ovarian, breast, lung, colorectal, pancreatic, nasopharyngeal (especially in Asian populations), and lymphoma. Risk factors for malignancy include older age, male sex, rapid onset, dysphagia, cutaneous necrosis, anti-TIF1-gamma positivity, and elevated ESR.

### The Debate

The optimal screening approach remains debated. An aggressive screening approach advocates for CT chest/abdomen/pelvis, colonoscopy, mammography, pelvic ultrasound with CA-125, PSA, nasopharyngeal endoscopy in appropriate populations, and PET/CT. A more conservative approach limits screening to age-appropriate cancer screening supplemented by targeted investigation based on symptoms and risk factors. There are no consensus guidelines, and practice varies between institutions and countries. The current trend favors a risk-stratified approach based on antibody status: anti-TIF1-gamma-positive patients warrant extensive screening, anti-Mi-2-positive patients require only standard age-appropriate screening, and anti-MDA5-positive patients have low malignancy risk, so the focus should shift to ILD screening instead.

### Recommended Screening Protocol (Many Centers)

Many centers recommend a thorough history, review of systems, and physical examination including pelvic and rectal examinations; baseline labs including CBC, CMP, and LFTs; CT chest/abdomen/pelvis with contrast or PET/CT; mammography for females; pelvic ultrasound with CA-125 for females; PSA for males over 50; colonoscopy for patients over 45 or earlier if at high risk; and age-appropriate cancer screening. Screening should be repeated at 6-12 months and annually for 3-5 years. Nasopharyngeal endoscopy is recommended in Southeast Asian patients.

<image>Screening algorithm for malignancy in adult-onset dermatomyositis stratified by myositis-specific antibody status showing intensive screening for anti-TIF1-gamma positive patients and ILD-focused evaluation for anti-MDA5 positive patients</image>

## Treatment

### Skin Disease

Strict sun avoidance and broad-spectrum SPF 50+ sunscreen form the foundation of skin management. Moderate-to-high potency topical corticosteroids are used for the body, with low-potency formulations for the face and eyelids. Topical calcineurin inhibitors are preferred for facial involvement as steroid-sparing agents. Hydroxychloroquine at 200-400 mg/day is commonly used, although DM patients may have higher rates of drug eruptions from hydroxychloroquine, occurring in approximately 25% of patients. Methotrexate is effective for both skin and mild muscle disease. Mycophenolate mofetil addresses both skin and muscle. IVIG is effective for skin-predominant disease but is typically reserved for refractory cases.

### Muscle Disease

Systemic corticosteroids, usually prednisone at 1 mg/kg/day with a gradual taper over months, are the initial treatment for muscle disease. Steroid-sparing agents include methotrexate, azathioprine, and mycophenolate mofetil. IVIG is effective for refractory myositis, and rituximab serves as an option for refractory cases. Physical therapy and rehabilitation are essential components of care.

### Rapidly Progressive ILD (Anti-MDA5+)

RP-ILD in anti-MDA5-positive patients requires aggressive immunosuppression with high-dose corticosteroids combined with a calcineurin inhibitor (tacrolimus or cyclosporine) and cyclophosphamide, often referred to as triple therapy. Rituximab is used for refractory cases. Tofacitinib, a JAK inhibitor, has emerging evidence for anti-MDA5-positive DM with RP-ILD. Lung transplant evaluation is considered when disease is refractory to medical therapy.

### Calcinosis

Calcinosis is notoriously difficult to treat, with limited evidence supporting any single modality. Options include diltiazem, colchicine, bisphosphonates, IVIG, sodium thiosulfate, and surgical excision. It is more common in juvenile DM and may improve over the course of years.

## Clinical Pearls

Gottron papules over the knuckles versus lupus which involves the interarticular spaces (between the knuckles) is one of the most commonly tested clinical distinctions in dermatology. Anti-TIF1-gamma is the antibody most strongly associated with malignancy in adult DM, and its presence should trigger an aggressive and repeated cancer search. Anti-MDA5 DM can present with minimal muscle involvement but rapidly fatal ILD; skin ulceration over Gottron papules and painful palmar papules are clinical clues. The heliotrope rash can be extremely subtle, especially in darker skin types, so clinicians should look for periorbital edema with a faint violaceous hue. Hydroxychloroquine can paradoxically worsen or cause drug eruptions in up to 25% of DM patients, and patients should be monitored closely after initiation.

## References
- Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387-408
- Trallero-Araguas E, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis. Medicine. 2012;91(2):76-83
- Fiorentino D, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5. Medicine. 2011;90(4):282-290
- Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):28
- Moghadam-Kia S, et al. Risk of malignancy and screening strategies in dermatomyositis. Curr Rheumatol Rep. 2023;25(3):38-47